GH Research PLC (GHRS) - Total Assets
Based on the latest financial reports, GH Research PLC (GHRS) holds total assets worth $288.23 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GHRS equity financing ratio to measure how much of total assets are equity-financed.
GH Research PLC - Total Assets Trend (2019–2025)
This chart illustrates how GH Research PLC's total assets have evolved over time, based on quarterly financial data. Explore GH Research PLC long-term investment allocation to see how much of total assets are deployed in long-term investments.
GH Research PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
GH Research PLC's total assets of $288.23 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.4% |
| Accounts Receivable | $1.29 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how GH Research PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GH Research PLC (GHRS) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GH Research PLC's current assets represent 99.2% of total assets in 2025, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 85.4% of total assets in 2025, down from 98.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
GH Research PLC Competitors by Total Assets
Key competitors of GH Research PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
GH Research PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 34.13 | 17.23 | 4.46 |
| Quick Ratio | 34.13 | 17.23 | 4.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $277.60 Million | $145.27 Million | $4.30 Million |
GH Research PLC - Advanced Valuation Insights
This section examines the relationship between GH Research PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.25 |
| Latest Market Cap to Assets Ratio | 5.09 |
| Asset Growth Rate (YoY) | 53.1% |
| Total Assets | $288.23 Million |
| Market Capitalization | $1.47 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values GH Research PLC's assets at a significant premium (5.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: GH Research PLC's assets grew by 53.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GH Research PLC (2019–2025)
The table below shows the annual total assets of GH Research PLC from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $288.23 Million | +53.09% |
| 2024-12-31 | $188.27 Million | -16.80% |
| 2023-12-31 | $226.30 Million | -11.03% |
| 2022-12-31 | $254.36 Million | -9.13% |
| 2021-12-31 | $279.92 Million | +4634.84% |
| 2020-12-31 | $5.91 Million | +1073.02% |
| 2019-12-31 | $504.00K | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more